// Weimin Ye 1 , Ellen T. Chang 2, 3 , Zhiwei Liu 1 , Qing Liu 4, 5 , Yonglin Cai 6, 7 , Zhe Zhang 8, 9 , Guomin Chen 10 , Qi-Hong Huang 11 , Shang-Hang Xie 4, 5 , Su-Mei Cao 4, 5 , Jian-Yong Shao 5 , Wei-Hua Jia 5 , Yuming Zheng 6, 7 , Jian Liao 12 , Yufeng Chen 9 , Longde Lin 9 , Liming Liang 13, 14 , Ingemar Ernberg 15 , Thomas L. Vaughan 16, 17 , Guangwu Huang 8, 9, * , Yi Zeng 10, * , Yi-Xin Zeng 5, 18, * and Hans-Olov Adami 1, 13, * 1 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden 2 Exponent, Inc., Health Sciences Practice, Menlo Park, CA, USA 3 Division of Epidemiology, Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA, USA 4 Department of Cancer Prevention Center, Sun Yat-sen University Cancer Center, Guangzhou, China 5 State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China 6 Department of Clinical Laboratory, Wuzhou Red Cross Hospital, Wuzhou, China 7 Wuzhou Health System Key Laboratory for Nasopharyngeal Carcinoma Etiology and Molecular Mechanism, Wuzhou, China 8 Department of Otolaryngology-Head & Neck Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, China 9 Key Laboratory of High-Incidence-Tumor Prevention & Treatment (Guangxi Medical University), Ministry of Education, Nanning, China 10 State Key Laboratory for Infectious Diseases Prevention and Control, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China 11 Sihui Cancer Institute, Sihui, China 12 Cangwu Institute for Nasopharyngeal Carcinoma Control and Prevention, Wuzhou, China 13 Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA 14 Department of Biostatistics, Harvard TH Chan School of Public Health, Boston, MA, USA 15 Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden 16 Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA 17 Department of Epidemiology, University of Washington, Seattle, WA, USA 18 Beijing Hospital, Beijing, China * These authors have contributed equally to this work Correspondence to: Weimin Ye, email: weimin.ye@ki.se Keywords: case-control study, nasopharyngeal carcinoma, china Received: April 26, 2017 Accepted: July 03, 2017 Published: July 29, 2017 ABSTRACT With its population of over 1.3 billion persons, China offers abundant opportunities to discover causes of disease. However, few rigorous population-based case-control studies have as yet been conducted in mainland China. We conducted a population-based case-control study of nasopharyngeal carcinoma in Guangdong Province and Guangxi Autonomous Region. We collected questionnaires and biospecimens from incident cases recruited between March 2010 and December 2013, and population-based controls between November 2010 and November 2014. Preparatory activities prior to subject enrollment required approximately 18 months. We enrolled a total of 2554 NPC cases and 2648 controls. Among all identified cases, 83.8% participated. For the participating cases, the median time between diagnosis and interview was 2 days. Among all contacted controls, 82.7% participated. From the enrolled cases, we collected 2518 blood specimens (provided by 98.6% of eligible cases), 2350 saliva specimens (92.0%), 2514 hair specimens (98.4%), and 2507 toenail/fingernail specimens (98.2%). From the enrolled controls, we collected 2416 blood specimens (91.2%), 2505 saliva specimens (94.6%), 2517 hair specimens (95.1%), and 2514 toenail/fingernail specimens (94.9%). We demonstrate that population-based epidemiologic research can successfully be conducted in southern China. The study protocols, databases, and biobank will serve as an extraordinarily valuable resource for testing future etiologic hypotheses.